HIV, Antiretroviral Therapy, and Hypertensive Disorders in Pregnancy: A Systematic Review and Meta-analysis
Overview
Authors
Affiliations
Background: There are data to suggest that infection with HIV or use of highly active antiretroviral therapy increases the risk of hypertensive disorders in pregnancy. This systematic review and meta-analysis aims to provide an overview of the research hitherto.
Methods: A systematic review of EMBASE, PubMed, and The Cochrane Library databases was conducted to obtain articles about the association between HIV in pregnancy and/or HIV therapy and the risk of developing pregnancy-induced hypertension (PIH), pre-eclampsia, eclampsia, or Hemolysis Elevated Liver enzymes Low Platelet count syndrome. Quality of articles was evaluated with an adapted Cochrane Collaboration bias assessment tool. Relative risks (RRs) were pooled with a random-effects meta-analysis weighted by the inverse of their variance.
Results: Of the 2136 articles screened, 28 studies were eligible for inclusion; 15 studies reported on the association with PIH, 16 on pre-eclampsia, 5 on eclampsia, and 3 articles on HIV therapy regimens. All articles had a high risk of bias, and between-study heterogeneity was considerable. Based on the meta-analysis, there does not seem to be an association between HIV and PIH [RR 1.26, 95% confidence interval (CI): 0.87 to 1.83, I = 78.6%], pre-eclampsia (RR 1.01, 95% CI: 0.87 to 1.18, I = 63.9%), or eclampsia (RR 1.61, 95% CI: 0.14 to 18.68, I = 97.0%). A meta-analysis of the association with HIV therapy and risk of hypertensive disorders in pregnancy could not be performed.
Conclusions: This meta-analysis shows no significant association between HIV positivity and PIH, pre-eclampsia, or eclampsia. However, the high risk of bias within most studies limits the strength of conclusions and well-designed studies are necessary to confirm or refute these findings.
Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.
Henderson A, Cholli P, Lampe M, Kourtis A Expert Rev Anti Infect Ther. 2024; 22(4):153-167.
PMID: 38517686 PMC: 11287786. DOI: 10.1080/14787210.2024.2334054.
Bengtson A, Madlala H, Matjila M, Goedecke J, Cu-Uvin S, McGarvey S Open Forum Infect Dis. 2024; 11(3):ofae093.
PMID: 38481429 PMC: 10932940. DOI: 10.1093/ofid/ofae093.
Beck K, Cowdell I, Portwood C, Sexton H, Kumarendran M, Brandon Z Front Med (Lausanne). 2024; 11:1323813.
PMID: 38476445 PMC: 10927998. DOI: 10.3389/fmed.2024.1323813.
Antiretroviral Options and Treatment Decisions During Pregnancy.
Poliektov N, Badell M Paediatr Drugs. 2023; 25(3):267-282.
PMID: 36729360 DOI: 10.1007/s40272-023-00559-w.
Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV.
Eke A, Mirochnick M, Lockman S N Engl J Med. 2023; 388(4):344-356.
PMID: 36720135 PMC: 10400304. DOI: 10.1056/NEJMra2212877.